The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol
Open accessAbstract
The proliferation and differentiation of normal prostate epithelial cells depends upon the action of androgens produced by the testis. Prostate cancers retain the ability to respond to androgens in the initial stages of cancer development, but progressively become independent of exogenous androgens in advanced stages of the disease while maintaining the expression of functional androgen receptor (AR). In the present study, we have determined the potential of prostate cancer cells to synthesize androgens from cholesterol which may be involved in intracrine regulation of AR in advanced stages of the disease‥ Established androgen- independent prostate cancer cell lines, PC3 and DU145 cells, expressed mRNA and proteins for scavenger receptor type B1 (SRB1), steroidogenic acute regulatory (StAR) protein, cytochrome P450 cholesterol side chain cleavage (P450scc), 3β-hydroxysteroid dehydrogenase (3β-HSD) and other enzymes involved in androgen biosynthesis. Expression of all these proteins and enzymes was significantly higher in the androgen-independent derivative of LNCaP prostate cancer cells (C81) than in the androgen-dependent cell line (C33). In serum-free cultures, the androgen-independent C81 cells secreted ~5 fold higher testosterone than C33 cells as determined in the conditioned media by immunoassays. These cells could also directly convert radioactive cholesterol into testosterone which was identified by thin layer chromatography. These results for the first time show that prostate cancer cells in advanced stages of the disease could synthesize androgens from cholesterol and hence are not dependent upon testicular and/or adrenal androgens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The development of androgen-independent prostate cancer.
Feldman, B. J., & Feldman, D. (2001) · Nature reviews. Cancer · doi:10.1038/35094009 · Cited by 2,326
Molecular determinants of resistance to antiandrogen therapy
Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L. (2004) · Nature Medicine · doi:10.1038/nm972 · Cited by 2,278
Stanbrough, M., Bubley, G. J., Ross, K., Golub, T. R., Rubin, M. A., Penning, T. M., Febbo, P. G., & Balk, S. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4000 · Cited by 1,082
StAR protein and the regulation of steroid hormone biosynthesis.
Stocco, D. M. (2001) · Annual Review of Physiology · doi:10.1146/annurev.physiol.63.1.193 · Cited by 917
The Androgen Axis in Recurrent Prostate Cancer
Mohler, J. L., Gregory, C. W., Ford, O. H., Kim, D., Weaver, C. M., Petrusz, P., Wilson, E. M., & French, F. S. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1146-03 · Cited by 675
Holzbeierlein, J., Lal, P., LaTulippe, E., Smith, A., Satagopan, J., Zhang, L., Ryan, C., Smith, S., Scher, H., Scardino, P., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63112-4 · Cited by 577
Mostaghel, E. A., Page, S. T., Lin, D. W., Fazli, L., Coleman, I. M., True, L. D., Knudsen, B., Hess, D. L., Nelson, C. C., Matsumoto, A. M., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3332 · Cited by 529
Testosterone and Dihydrotestosterone Tissue Levels in Recurrent Prostate Cancer
Titus, M. A., Schell, M. J., Lih, F. B., Tomer, K. B., & Mohler, J. L. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0525 · Cited by 488
Watari, H., Arakane, F., Moog-Lutz, C., Kallen, C. B., Tomasetto, C., Gerton, G. L., Rio, M.-C., Baker, M. E., & Strauss, J. F. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.16.8462 · Cited by 247
Research works printed but not linked: 20
- Cai, 2007, Androgen regulation of soluble guanylyl cyclasealpha1 mediates prostate cancer cell proliferation, Oncogene, 26, 1606, 10.1038/sj.onc.1209956 · DOI
- Cao, 2006, Regulator of G-protein signaling 2 (RGS2) inhibits androgen-independent activation of androgen receptor in prostate cancer cells, Oncogene, 25, 3719, 10.1038/sj.onc.1209408 · DOI
- Castagnetta, 1997, Expression of different 17beta-hydroxysteroid dehydrogenase types and their activities in human prostate cancer cells, Endocrinology, 138, 4876, 10.1210/en.138.11.4876 · DOI
- Chen, 2007, Prostate-derived factor as a paracrine and autocrine factor for the proliferation of androgen receptor-positive human prostate cancer cells, Prostate, 67, 557, 10.1002/pros.20551 · DOI
- Denmeade, 2003, Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models, Prostate, 54, 249, 10.1002/pros.10199 · DOI
- El-Alfy, 1999, Localization of type 5 17beta-hydroxysteroid dehydrogenase, 3beta-hydroxysteroid dehydrogenase, and androgen receptor in the human prostate by in situ hybridization and immunocytochemistry, Endocrinology, 140, 1481, 10.1210/en.140.3.1481 · DOI
- Ellem, 2006, Aromatase and prostate cancer, Minerva Endocrinol., 31, 1
- Ellem, 2004, Local aromatase expression in human prostate is altered in malignancy, J. Clin. Endocrinol. Metab., 89, 2434, 10.1210/jc.2003-030933 · DOI · Paper page
- Gelmann, 2002, Molecular biology of the androgen receptor, J. Clin. Oncol., 20, 3001, 10.1200/JCO.2002.10.018 · DOI · Paper page
- Griffiths, 1997, Androgens, androgen receptors, antiandrogens and the treatment of prostate cancer, Eur. Urol., 32, 24
- Hara, 2003, Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline, Cancer Res., 63, 5622
- Igawa, 2002, Establishment and characterization of androgen-independent human prostate cancer LNCaP cell model, Prostate, 50, 222, 10.1002/pros.10054 · DOI · Paper page
- Ismail, 1972, Radioimmunoassay of testosterone without chromatography, J. Clin. Endocrinol. Metab., 34, 177, 10.1210/jcem-34-1-177 · DOI · Paper page
- Jemal, 2005, Trends in the leading causes of death in the United States, 1970–2002, JAMA, 294, 1255, 10.1001/jama.294.10.1255 · DOI · Paper page
- Kaplan, 1969, Estrogens and cancer of the prostate, Surg. Gynecol. Obstet., 128, 117
- Labrie, 1997, The key role of 17 beta-hydroxysteroid dehydrogenases in sex steroid biology, Steroids, 62, 148, 10.1016/S0039-128X(96)00174-2 · DOI · Paper page
- Millena, 2004, Autocrine regulation of steroidogenic function of Leydig cells by transforming growth factor-alpha, Mol. Cell. Endocrinol., 224, 29, 10.1016/j.mce.2004.07.004 · DOI
- Nakamura, 2005, In situ androgen producing enzymes in human prostate cancer, Endocr. Relat. Cancer, 12, 101, 10.1677/erc.1.00914 · DOI
- Schmidt, 2005, Androgen conversion in osteoarthritis and rheumatoid arthritis synoviocytes—androstenedione and testosterone inhibit estrogen formation and favor production of more potent 5alpha-reduced androgens, Arthritis Res. Ther., 7, R938, 10.1186/ar1769 · DOI
- Unni, 2004, Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence, Cancer Res., 64, 7156, 10.1158/0008-5472.CAN-04-1121 · DOI · Paper page
Cited by
Harris, W. P., Mostaghel, E. A., Nelson, P. S., & Montgomery, B. (2009) · Nature Clinical Practice Urology · doi:10.1038/ncpuro1296 · Cited by 877
Cai, C., Chen, S., Ng, P., Bubley, G. J., Nelson, P. S., Mostaghel, E. A., Marck, B., Matsumoto, A. M., Simon, N. I., Wang, H., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0532 · Cited by 433
Androgen receptors in hormone-dependent and castration-resistant prostate cancer
Shafi, A. A., Yen, A. E., & Weigel, N. L. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.07.003 · Cited by 420
Yuan, X., Cai, C., Chen, S., Chen, S., Yu, Z., & Balk, S. P. (2014) · Oncogene · doi:10.1038/onc.2013.235 · Cited by 370
Cruz, P. M. R., Mo, H., McConathy, W. J., Sabnis, N., & Lacko, A. G. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00119 · Cited by 349
Metadata
- Authors
- Dillard, P. R., Lin, M.-F., & Khan, S. A.
- Venue
- Molecular and Cellular Endocrinology
- Publisher
- Elsevier BV
- Published
- 2008-11
- Volume
- 295
- Issue
- 1-2
- Pages
- 115-120
- ISSN
- 0303-7207 (ISSN-L)
- OpenAlex
- W2075379080
- Cited by
- 225
- References
- 9
- FWCI
- 13.63
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.